As it has done with so much else in healthcare, COVID-19 dominated our 2020 annual pharmacy survey. The disease was addressed in 10 of our 13 areas we covered, either within the question itself or as a possible answer. Second of three parts. See more in our Surveys tab.
As it has done with so much else in healthcare, COVID-19 dominated our 2020 annual pharmacy survey. The disease was addressed in 10 of our 13 areas we covered, either within the question itself or as a possible answer. First of three parts. See more in our Surveys tab.
Senior Vice President and Chief Pharmacy Officer for Optum Rx and member of the Managed Healthcare Executive® Editorial Advisory Board, David Calabrese, provides his commentary on the future of pharmacy care services after the coronavirus pandemic.
MHE's Briana Contreras spoke with CEO of Scripta, Eric Levin. The two discussed the current state of the pharmacy benefit market and how the Scripta organization has been assisting its clients and their prescriptions prior to the COVID-19 pandemic and during.
SingleCare analyzed consumer prescription demand and fill data in the weeks leading up to shelter in place orders, beginning in March, and the subsequent months after the pandemic to see how COVID has impacted the healthcare trends of Americans.
From staffing to readmissions to diagnostics, data intelligence is poised to revolutionize healthcare.
In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
The two PCSK9 inhibitors have fallen far short of expectations. Inclisiran, which works by RNA inference, only needs to be injected twice a year.
Pharmacy benefit managers are taking steps to be more responsible for the total cost of care and to become more transparent, while adding technology tools to support patients, payers and physicians in a post-COVID-19 world.
Drug makers around the world are racing to develop the first effective COVID-19 vaccine. Early efforts show promise, but an anticipated jump in the novel coronavirus cases in the fall means the sooner a vaccine is developed, the more lives can be saved-and the pharmaceutical industry plays a major role in this discovery.
The Institute for Clinical and Economic Review (ICER) found siponimod has benefits for patients with active secondary progressive multiple sclerosis, but its benefits were in line with other therapies in a crowded marketplace.
Tagrisso, the targeted therapy made by AstraZeneca, could become the treatment of choice for the majority of lung cancer patients with mutations in a certain gene who are treated after surgery, based on findings presented this past weekend at the American Society of Clinical Oncology annual meeting.
He was reluctant to take the CEO job, but VanTrieste has the unique nonprofit drug manufacturer surpassing its goals and possibly branching out into the retail market.
A new study highlights the role a qualified specialty pharmacist can play in driving down costs across a health plan.
A study of patients with inflammatory conditions who were prescribed biologic disease-modifying anti-rheumatic drugs had lower rates of chronic opioid use if they were adherent to their biologic therapy, according to new research.
Taiwan has had only 6 COVID-19-related deaths. The country used community pharmacists to subdue the outbreak.
The opioid epidemic is far from over, but it may slip behind other challenges. COVID-19 obviously tops the list of new problems and drug pricing and affordability will continue to soak up time and attention.
DMARDs and the JAK Inhibitors have improved RA treatment. But not many new drugs are in the offing at the moment.
The "interactive modeler" will allow users to plug in their own assumptions.
Our roundup of PBMI2020 meeting so far
New point-of-care tools offer greater transparency.
Express Scripts’ annual Drug Trend Report highlights top contributors to prescription drug spending in 2019.
Trade group had previously documented even slower coverage by Part D plans.
